Abstract: Improved methods and novel compositions for identifying peptides and single-chain antibodies that bind to predetermined receptors or epitopes. Such peptides and antibodies are identified by improved and novel methods for affinity screening of polysomes displaying nascent peptides.
Abstract: The invention provides a bcl-2 related protein, Bad, Bad muteins, two-hybrid systems comprising interacting Bad polypeptide sequences, Bad polynucleotides, and uses thereof.
Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies of multiple isotypes. Heterologous antibodies are encoded by immunoglobulin heavy chain genes not normally found in the genome of that species of non-human animal. In one aspect of the invention, one or more transgenes containing sequences that permit isotype switching of encoded unrearranged heterologous human immunoglobulin heavy chains are introduced into a non-human animal thereby forming a transgenic animal capable of producing antibodies of various isotypes encoded by human immunoglobulin genes. Such heterologous human antibodies are produced in B-cells which are thereafter immortalized, e.g., by fusing with an immortalizing cell line such as a myeloma or by manipulating such B-cells by other techniques to perpetuate a cell line capable of producing a monoclonal heterologous antibody.
Abstract: This invention relates to the use of promoters for ribonucleic acid amplification and other genetic manipulations. Processes are provided wherein complementary deoxyribonucleic acid (cDNA) is synthesized from a ribonucleic acid (RNA) sequence using a complementary primer linked to an RNA polymerase promoter region complement and then anti-sense RNA (aRNA) is transcribed from the cDNA by introducing an RNA polymerase capable of binding to the promoter region. Additional processes using the resulting aRNA are also described.
Type:
Grant
Filed:
October 5, 1992
Date of Patent:
August 13, 1996
Inventors:
Russell N. Van Gelder, Mark E. Von Zastrow, Jack D. Barchas, James H. Eberwine
Abstract: Methods and composition are provided for identifying antiproliferative polypeptides which inhibit clonal expansion and/or induce apoptosis in cells of a predetermined cell population (e.g., a neoplastic cell sample) expressing a cell surface receptor which is a member of the immunoglobulin superfamily. A predetermined cell population expressing surface immunoglobulin superfamily molecules is isolated from a patient as a cellular sample, such as a lymph node biospy or blood sample containing neoplastic lymphocytic cells. Antiproliferative peptides which are identified by the methods of the invention can be used as therapeutic agents for treating lymphoproliferative disorders by anti-idiotype therapy.
Type:
Grant
Filed:
February 5, 1993
Date of Patent:
April 30, 1996
Inventors:
Markus F. Renschler, Ronald Levy, Ramesh R. Bhatt, William J. Dower
Abstract: Methods and compositions are described for immobilizing anti-ligands, such as antibodies or antigens, hormones or hormone receptors, oligonucleotides, and polysaccharides on surfaces of solid substrates for various uses. The methods provide surfaces covered with caged binding members which comprise protecting groups capable of being removed upon application of a suitable energy source. Spatially addressed irradiation of predefined regions on the surface permits immobilization of anti-ligands at the activated regions on the surface. Cycles of irradiation on different regions of the surface and immobilization of different anti-ligands allows formation of an immobilized matrix of anti-ligands at defined sites on the surface. The immobilized matrix of anti-ligands permits simultaneous screenings of a liquid sample for ligands having high affinities for certain anti-ligands of the matrix. A preferred embodiment of the invention involves attaching photoactivatable biotin derivatives to a surface.
Type:
Grant
Filed:
April 23, 1993
Date of Patent:
January 9, 1996
Assignee:
Affymax Technologies N.V.
Inventors:
Ronald W. Barrett, Michael C. Pirrung, Lubert Stryer, Christopher P. Holmes, Steven A. Sundberg
Abstract: The invention provides antioxidant salen-metal complexes in a form suitable for pharmaceutical administration to treat or prevent a disease associated with cell or tissue damage produced by free radicals such as superoxide.